---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-096245"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:16:30.074695+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics enters $20.6M stock purchase agreement and shareholders approve reverse split and equity plan

## Summary
- Entered into a purchase agreement with Keystone Capital Partners, LLC to sell up to $20,589,384.23 of common stock.
- Shareholders approved a reverse stock split at a ratio between 1:25 and 1:150, set by the board.
- Shareholders approved issuance of shares upon conversion of Series C Preferred and exercise of warrants from September 2024.
- Shareholders approved an increase of 20,845,391 shares under the 2024 Equity Incentive Plan.
- Company had previously sold 23,377,921 shares for $4.41 million under the prior purchase agreement.

## SEC filing metadata
- accession: 0001213900-24-096245
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390024096245/0001213900-24-096245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390024096245/ea0220614-8k_cerothera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-096245
- JSON: https://secwatch.observer/filing/0001213900-24-096245.json
- Plain text: https://secwatch.observer/filing/0001213900-24-096245.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.